Boomerang Biopathways is a leading provider of early clinical trial services, specializing in helping BioPharma and MedTech companies conduct clinical trials in Australia. Our mission is to accelerate clinical outcomes by leveraging Australia’s unique advantages—speed, cost-efficiency, and high-quality data. From legal setup to full trial execution, we offer comprehensive support, enabling companies to bring innovative therapies to market faster while enhancing value creation. With a team of… Show more Boomerang Biopathways is a leading provider of early clinical trial services, specializing in helping BioPharma and MedTech companies conduct clinical trials in Australia. Our mission is to accelerate clinical outcomes by leveraging Australia’s unique advantages—speed, cost-efficiency, and high-quality data. From legal setup to full trial execution, we offer comprehensive support, enabling companies to bring innovative therapies to market faster while enhancing value creation. With a team of seasoned experts and a focus on seamless trial management, Boomerang Biopathways is the trusted partner for global companies seeking to optimize their clinical development programs in Australia. Show less

Venture studio and corporate advisory firm specialising in the commercialisation of life science innovations from universities and medical research institutes. We assist spinouts and established health sector companies with corporate structuring and facilitate capital raising through our network of family offices and private investors.

Executive management of UNSW spin-out biotech company developing small molecule kinase inhibitors that control alternative RNA splicing for treatment of osteoarthritis, chronic pain and cancer.

Operational management of UQ spinout developing a biologic therapeutic for the treatment of non-alcoholic steatohepatitis (NASH). Led investment into company by IP Group before moving into operational role in company.

Senior membor in Life Science investment team in Australian office of London-based global Venture Capital firm. Reviewed 100+ opportunities arising from Go8 and Auckland University technologies, wrote investment proposals and led investments into two spin-out companies: Jetra Therapeutics and Kira Biotech.

The NUS Industry Liaison Office (ILO) encourages entrepreneurship and commercialisation activities for National University of Singapore researchers and students. The Life Sciences team is responsible for developing and commercialising new technologies and intellectual property arising from NUS research in the biological and medical sciences.As Associate Director my role was to lead a team of Technology Commercialisation Managers and ensure they worked effectively with inventors to :… Show more The NUS Industry Liaison Office (ILO) encourages entrepreneurship and commercialisation activities for National University of Singapore researchers and students. The Life Sciences team is responsible for developing and commercialising new technologies and intellectual property arising from NUS research in the biological and medical sciences.As Associate Director my role was to lead a team of Technology Commercialisation Managers and ensure they worked effectively with inventors to : - generate commercial and technical development strategies for early stage technologies - provide support for technology development through effective IP protection and patent filings, funding of translation projects via our internal Technology Access Programme (TAP) and access to ILO programmes including JumpStart, Lean Launch Pad and Minimum Viable Product studio.- market technologies to industry and investors- assist in business planning and pitches for funding of spin-out companies- negotiate and execute licensing deals The Life Sciences team has extensive experience in forming spin-out companies based on NUS technologies and in negotiating technology licensing deals with a range of partners from major pharmaceutical companies to SMEs to VC investors. Show less

LifeArc (formerly MRC Technology) is an independent medical research charity that collaborates with academic scientists and biotechs on early stage small molecule and antibody-based drug discovery projects. It aims to help academics translate their research by collaborating to develop novel therapeutics and partner these to the pharmaceutical sector for clinical development and ultimately patient benefit. LifeArc works in any area of unmet clinical need and have a strong track record of… Show more LifeArc (formerly MRC Technology) is an independent medical research charity that collaborates with academic scientists and biotechs on early stage small molecule and antibody-based drug discovery projects. It aims to help academics translate their research by collaborating to develop novel therapeutics and partner these to the pharmaceutical sector for clinical development and ultimately patient benefit. LifeArc works in any area of unmet clinical need and have a strong track record of success, having helped developed the marketed drugs Keytruda (Merck), Actemra (Roche), Tysabri (Biogen Idec) and Entyvio (Takeda).As Business Development Manager my role involved scouting for new potential drug discovery projects in UK, Europe and US by visiting research institutions and meeting with scientists and TTOs. We offer a full suite of industry-standard drug discovery capabilities, including assay development, HTS, in silico and structural biology, medicinal chemistry, ADME, antibody humanisation and engineering. We operate a shared-risk model where both parties contribute to the project and we share revenues with our collaborators should the project be successful.Once projects have generated preclinical assets with therapeutic proof of concept in a relevant disease model and well-protected IP my role is also to out-license these to pharma companies for further clinical development.I also managed the Dementia Consortium, a unique partnership involving Alzheimer's Research UK, the pharma companies Lilly, Astex and Eisai and MRC Technology, that aims to accelerate the development of new therapeutics for neurodegenerative disease. Show less

LifeArc (formerly MRC Technology) is an independent medical research charity that helps MRC scientists translate their research by protecting, developing and commercialising new medical technologies for patient benefit.I was Business Manager for four MRC Units and worked closely with scientists to protect their IP (e.g. patent filing), identify and obtain translational funding (e.g. from MRC DPFS, Wellcome Trust), market the technology to potential commercial partners and negotiate… Show more LifeArc (formerly MRC Technology) is an independent medical research charity that helps MRC scientists translate their research by protecting, developing and commercialising new medical technologies for patient benefit.I was Business Manager for four MRC Units and worked closely with scientists to protect their IP (e.g. patent filing), identify and obtain translational funding (e.g. from MRC DPFS, Wellcome Trust), market the technology to potential commercial partners and negotiate commercial licence agreements. I was involved in development and commercialisation of a wide range of technologies, from novel therapeutics, to diagnostics, medical devices, software, reagents and equipment. Show less

Cambridge Enterprise is a wholly-owned subsidiary of the University of Cambridge and functions as the technology transfer office for University scientists. Cambridge Enterprise helps University employees protect and develop their inventions through licensing and spin-out routes (the latter through Cambridge Enterprise Seed Funds).My role involved facilitating the protection and commercial development of early-stage life science and medical technologies from across the University. This… Show more Cambridge Enterprise is a wholly-owned subsidiary of the University of Cambridge and functions as the technology transfer office for University scientists. Cambridge Enterprise helps University employees protect and develop their inventions through licensing and spin-out routes (the latter through Cambridge Enterprise Seed Funds).My role involved facilitating the protection and commercial development of early-stage life science and medical technologies from across the University. This encompassed a wide range of activities, including working with Seed Funds on spin-out creation, developing prototypes of new medical devices, protecting new inventions with patents, marketing technologies and negotiating agreements. Show less

Postdoctoral research in developmental vascular biology in the lab of Anne Eichmann, INSERM U36, Collége de France, Paris.My research established a role for the regulation of angiogenesis by the Notch ligand Delta-like 4, a major regulator of blood vessel growth in embryonic development and diseases such as cancer.

Worked in the lab of John Prins in Diabetes and Endocrinology, Department of Medicine at the Princess Alexandra Hospital.My research investigated mechanisms of adipocyte differentiation in patients with Type-2 Diabetes